Sinclair Research Appoints G. Alex Wakefield as Vice President of Research and Operations

COLUMBIA, Mo.--(BUSINESS WIRE)-- Sinclair Research, one of the nation’s leading providers of preclinical services, is pleased to announce new executive leadership with the arrival of G. Alex Wakefield, DVM, as vice president of research and operations. In this newly created role, Wakefield will have overall responsibility for the company’s research services and its operational processes. He will be responsible for driving the growth of Sinclair’s business model and fostering positive relationships with new and current customers.

Wakefield joins Sinclair Research from Covance in Greenfield, Ind., where he served in multiple areas including discovery science, toxicology, veterinary services, business development and management. He has held similar positions at Eli Lilly and Company. With more than 25 years of industry experience, Wakefield is an accomplished pharmaceutical development professional with extensive expertise in the science and management of drug development. His preclinical market knowledge and experience from the pharmaceutical and contract research organization industries will be of significant value to Sinclair and all its customers.

“Alex’s combination of experience across pharma and CRO services coupled with his scientific knowledge of both efficacy and safety animal modeling will enable Sinclair to move to the next level in size, scope and market leadership,” said Guy Bouchard, president. “2017 was an outstanding year for Sinclair Research, particularly related to GLP services and regulatory compliance. As a seasoned industry executive, Alex’s proven leadership skills will be invaluable as we continue to grow our business.”

About Sinclair Research
Sinclair Research Center, a preclinical contract research organization (CRO) established in 1964, offers animal efficacy models, IND enabling toxicology services and research capabilities to animal health and medical device companies. Our clients include large, mid-tier, small and startup companies in both human and animal health markets. With more than 20 years’ experience, Sinclair is the undisputed expert in all breeds of miniature swine. In addition, we manage many standing animal colony models including diabetes, wound healing, irritable bowel disease and general PK, and we have developed and maintain our own unique research breed of mini-swine, “The Sinclair Pig.”

View source version on businesswire.com: http://www.businesswire.com/news/home/20180206005262/en/